China's manufacturing overcapacity is creating a 'new China shock,' with its manufacturing trade surplus doubling to $1.9 trillion in five years and its share of global capacity projected to hit 45% by 2030.
faces critical supply chain vulnerabilities, with extreme dependence on China for essential inputs in pharmaceuticals (APIs, essential drugs) and electronics (printed circuit boards, legacy semiconductors).
China is deliberately deepening global reliance through state-directed industrial policies like 'Made in China 2025' and is willing to weaponize its dominance, as shown by recent export restrictions on critical minerals.
The hearing highlights the urgent need for a whole-of-government response, including updating U.S.
trade laws, investing in domestic manufacturing ecosystems, and coordinating with allies to build resilient alternative supply chains.
12 quotes
Concerns Raised
Extreme U.S. dependency on China for critical inputs in pharmaceuticals and electronics.
China's rapid and state-subsidized expansion of manufacturing capacity threatens to de-industrialize allied and emerging economies.
Beijing's demonstrated willingness to weaponize its supply chain dominance through export controls on critical materials.
Current U.S. trade laws are outdated and insufficient to counter China's sophisticated, non-market economic strategies.
Opportunities Identified
Investing in and reshoring domestic manufacturing for critical technologies like semiconductors and printed circuit boards.
Updating U.S. trade policy to address transnational subsidies and Chinese-owned production in third countries.
Strengthening alliances with partners to build resilient, diversified, and secure alternative supply chains.
Creating policies that drive domestic demand for U.S.-made components to ensure the long-term viability of new manufacturing investments.